{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Savardekar H"],"funding":["NCATS NIH HHS","NIAID NIH HHS","NIH Clinical Center","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["e181975"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12483567"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["135(19)"],"pubmed_abstract":["BRD4 is an epigenetic reader protein that regulates oncogenes such as myc in cancer. However, its additional role in shaping immune responses via regulation of inflammatory and myeloid cell responses is not yet fully understood. This work further characterized the multifaceted role of BRD4 in antitumor immunity. Nanostring gene expression analysis of EMT6 tumors treated with a BRD4 inhibitor identified a reduction in myeloid gene expression signatures. Additionally, BRD4 inhibition significantly reduced myeloid-derived suppressor cells (MDSCs) in the spleens and tumors of mice in multiple tumor models and also decreased the release of tumor-derived MDSC growth and chemotactic factors. Pharmacologic inhibition of BRD4 in MDSCs induced apoptosis and modulated expression of apoptosis regulato"],"journal":["The Journal of clinical investigation"],"pubmed_title":["BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy."],"pmcid":["PMC12483567"],"funding_grant_id":["K12 CA133250","T32 CA090223","P30 CA016058","T32 CA090223,K12CA133250-15,T32GM139784-03,UM1CA186712,P30 CA016058,T32AI106704,T32TR004543","T32 GM139784","T32 AI106704","T32 TR004543","UM1 CA186712"],"pubmed_authors":["Yu L","Schwarz E","Sun SH","Wesolowski R","Ozato K","Sabella J","DiVincenzo MJ","Sundi D","Carson WE","Parker R","Garbarine IC","Savardekar H","Li J","Lapurga G","Savardekar L","Stiff A","Benner B","Kendra KL","Wu RC","Xin G","Quiroga D","Zelinskas S","Dey A","Liu A","Abreo A","Scarberry L","Duggan MC","Hasanov M"],"additional_accession":[]},"is_claimable":false,"name":"BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy.","description":"BRD4 is an epigenetic reader protein that regulates oncogenes such as myc in cancer. However, its additional role in shaping immune responses via regulation of inflammatory and myeloid cell responses is not yet fully understood. This work further characterized the multifaceted role of BRD4 in antitumor immunity. Nanostring gene expression analysis of EMT6 tumors treated with a BRD4 inhibitor identified a reduction in myeloid gene expression signatures. Additionally, BRD4 inhibition significantly reduced myeloid-derived suppressor cells (MDSCs) in the spleens and tumors of mice in multiple tumor models and also decreased the release of tumor-derived MDSC growth and chemotactic factors. Pharmacologic inhibition of BRD4 in MDSCs induced apoptosis and modulated expression of apoptosis regulato","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T01:55:25.895Z","creation":"2026-05-04T03:14:12.4Z"},"accession":"S-EPMC12483567","cross_references":{"pubmed":["40762981"],"doi":["10.1172/JCI181975"]}}